Summary of Standard BioTools, Inc. Q1 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: $40.8 million, down 10% year-over-year, aligning with expectations.

Consumables Revenue: $14.5 million, down 16% year-over-year, impacted by lower demand in the Americas.

Instruments Revenue: $7.8 million, up 24% year-over-year, driven by growth in the spatial proteomics segment.

Services Revenue: $17.6 million, down 16% year-over-year, primarily due to a decline in lab services.

Net Loss: $26 million, an improvement from a loss of $32.2 million in Q1 2024.

Adjusted EBITDA: Loss of $16.9 million, improved from a loss of $23.7 million in Q1 2024.

Cash Position: $261 million in cash and equivalents, with no material debt.

Operating Expenses: Non-GAAP operating expenses decreased by 22% year-over-year to $38.6 million.

2Strategic Updates and Business Highlights

The company is focused on improving operational efficiency through the Standard BioTools Business System (SBS), which has led to significant cost reductions.

Recent product launches include the SomaScan offering and the CyTOF-XT Pro, aimed at enhancing the company's position in proteomics.

The partnership with Illumina is expected to expand the reach of SomaScan, although significant revenue from this collaboration is not anticipated until 2026.

The integration of SomaLogic has been successful, with over $80 million in cost reductions achieved since the merger.

3Forward Guidance and Outlook

Full-Year Revenue Guidance: Maintained at $165 million to $175 million, with expectations for a back-weighted revenue distribution.

Americas Academic Revenue: Anticipated mid-teens percentage decline, reflecting ongoing funding challenges.

Tariff Impact: Estimated low single-digit millions impact on gross margin and adjusted EBITDA, with plans to manage costs through pricing strategies.

4Bad News, Challenges, or Points of Concern

Market Headwinds: Continued challenges in U.S. academia and government funding, leading to delays in orders and project funding.

Revenue Declines: Notable decreases in consumables and services revenue due to project timing and funding uncertainties.

Tariff Complexity: New tariffs have added operational challenges, although the company views them as manageable.

Dependence on Large Customers: Revenue variability remains due to reliance on a few large accounts, which can obscure performance trends.

5Notable Q&A Insights

Revenue Split: Management indicated that the revenue split between the first and second halves of the year is expected to be driven by internal funnel metrics rather than traditional seasonality.

Instrument Demand: Positive growth in the sales funnel for instruments, particularly the Hyperion XTi, with no significant pull-forward effects noted.

M&A Strategy: The company remains committed to pursuing strategic acquisitions, with a disciplined approach to identifying opportunities in a changing market.

Biopharma Market: Healthy growth observed in the biopharmaceutical sector, with no significant changes in spending patterns reported. Overall, Standard BioTools is navigating a challenging market environment while focusing on operational improvements and strategic growth initiatives, particularly in proteomics and through partnerships.